

12 October 2022

Te Whatu Ora
Health New Zealand

Tēnā koe [REDACTED]

Your Official Information Act request, reference: [REDACTED]

Thank you for your email of 26 September 2022, asking for the following which has been considered under the Official Information Act 1982 (the Act):

Clostridium botulinum type A toxin (Botox, Dysport) is fully funded in Health NZ hospitals without restriction. Pharmac have reported that Waikato DHB hospital used 991 vials of Botox and Dysport for the year ended 30 June 2021. <https://pharmac.govt.nz/news-and-resources/official-information-act/official-information-act-responses/clostridium-botulinum-type-a-toxin-gross-spend-and-units-purchased-in-dhb-hospitals-yearly-from-1-july-2017-to-30-june-2021/>

We would like to understand how it is being used in the hospital. Please can you or your pharmacy department provide the number of vials used for the 1 July 2020 to 30 June 2021 financial year by department (Urology, Neurology, Rehab, Dermatology, Ophthalmology, any other (please specify) for each of Botox and Dysport? Please find attached a spreadsheet to help with the data collation.

Please find attached the spreadsheet you provided, completed with the requested information.

How to get in contact: If you have any questions, you can contact us via email - oiact@waikatodhb.health.nz. Also linked here refer to our website for general information and guidance regarding the Official Information Act - <https://www.waikatodhb.health.nz/about-us/official-information-act/>

If you are not happy with this response, you have the right to make a complaint to the Ombudsman. Information about how to do this is available at www.ombudsman.parliament.nz or by phoning 0800 802 602.

As this information may be of interest to other members of the public, Te Whatu Ora - Health New Zealand Waikato has decided to proactively release a copy of this response on our website found here <https://www.waikatodhb.health.nz/about-us/official-information-act/>. All requester data, including your name and contact details, will be removed prior to release.

Nāku iti noa, nā



Chris Lowry

**Interim District Co-Director | Tumū Whakahaere ā Takiwā
Waikato**

[TeWhatuOra.govt.nz](https://www.TeWhatuOra.govt.nz)

Private Bag 3240, Hamilton, 3200
Waea pūkoro: 07 839 8899

Te Kāwanatanga o Aotearoa
New Zealand Government

Clostridium botulinum type A toxin use by department in Waikato hospital

For the year ended 30 June 2021, Pharmac reported that Waikato hospital used 991 vials of Clostridium botulinum type A toxin (both brands).
Please can you advise how these vials were used within the hospital by department?

Table 1: Units used by department in the hospital for the year 1 July 2020 to 30 June 2021	Urology	Neurology	Rehab	Dermatology	Ophthalmology	Other (please specify)	Total
Clostridium botulinum type A toxin (Botox 100 unit vial)	52 units	702	0	0	7	281*	1042 units
Clostridium botulinum type A toxin (Dysport 300 unit vial)	0	0	0	0	0	0	0
Clostridium botulinum type A toxin (Dysport 500 unit vial)	0	0	0	0	0	0	0
Total							

*Other:

- Main operating theatre
- Dental
- Maxillofacial
- Meade clinical centre outpatients clinics
- Day of Surgery unit
- Medical ward
- ENT ward
- Thames hospital theatre
- Interventional radiology